39.5 billion tenge in private investment will be used to expand pharmaceutical production in Shymkent.
As part of the Head of State's instructions to increase the share of Kazakhstani production in the pharmaceutical industry, the Government of the Republic of Kazakhstan approved an Investment Agreement between the Ministry of Health of the Republic of Kazakhstan and JSC Khimfarm for the project "Providing the population with more affordable medicines and increasing the share of domestic drug production in the pharmaceutical industry of the Republic of Kazakhstan."
The corresponding decree was signed by Prime Minister of the Republic of Kazakhstan Olzhas Bektenov. The project aims to increase the share of Kazakhstani manufacturers, strengthen the country's drug security, and attract investment. The agreement marks the start of a new phase of Polpharma Santo's major investment project in Shymkent, creating 300 new jobs. The total private investment amounts to 39.5 billion tenge, including investments in scientific research. The first phase of the new production is scheduled to launch by the end of 2029.
The new facilities will enable the production of 38 types of medications for the treatment of the most common diseases—oncology, cardiovascular diseases, infectious diseases, and chronic illnesses, including tuberculosis. Production will meet international quality standards.